Treatment patterns and survival outcomes of early-onset colorectal cancer patients in Alberta, Canada: a population-based study

被引:13
作者
O'Sullivan, Dylan E. [1 ,2 ,3 ]
Cheung, Winson Y. [1 ,2 ]
Boyne, Devon J. [1 ,2 ]
Jarada, Tamer N. [1 ]
Tang, Patricia A. [2 ,4 ]
Gill, Sharlene [5 ]
Hilsden, Robert J. [1 ,3 ,6 ]
Brenner, Darren R. [1 ,2 ,3 ]
机构
[1] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada
[2] Univ Calgary, Dept Oncol, Calgary, AB, Canada
[3] Alberta Hlth Serv, Forzani & MacPhail Colon Canc Screening Ctr, Calgary, AB, Canada
[4] Univ Calgary, Cumming Sch Med, Dept Surg, Calgary, AB, Canada
[5] Univ British Columbia, Div Med Oncol, BC Canc, Vancouver, BC, Canada
[6] Univ Calgary, Cumming Sch Med, Dept Med, Calgary, AB, Canada
基金
加拿大健康研究院;
关键词
Early-onset colorectal cancer; treatment patterns; systemic therapy; radiation; survival outcomes; III COLON-CANCER; STAGE-II; ADJUVANT CHEMOTHERAPY; PULMONARY METASTASES; TREATMENT GUIDELINES; SURGICAL-TREATMENT; YOUNG-ONSET; ADHERENCE; RESECTION;
D O I
10.1016/j.ctarc.2022.100585
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The incidence of early-onset (<50) colorectal cancer (eoCRC) has been increasing in Canada. Little is known about treatment patterns and outcomes among this patient population in Canada.<br /> Patients and methods: We conducted a retrospective population-based cohort study of CRC patients in Alberta (2010-2018) using electronic medical records and administrative claims data. Treatment patterns and CRCspecific mortality were compared between early-onset age groups (<40 and 40-49) and average age-at-onset (60-70) (aoCRC) patients with multivariable logistic regression and cox proportional hazard models.<br /> Results: There were 334 and 935 patients in the early-onset groups and 4606 in the aoCRC group. Compared with aoCRC, patients <40 were more likely to receive chemotherapy in stage II colon (OR 3.41, CI 1.75-6.47) and stage III rectal (OR 3.01, CI 1.18-10.21), and to receive systemic therapy (OR 2.40, CI 1.46-4.12) and radiation in stage IV CRC (OR 2.70, CI 1.48-4.92). The 40-49 age group was more likely to receive chemotherapy in stage II colon (OR 2.13, CI 1.25-3.56), and chemoradiation in stage II rectal (OR 2.16, CI 1.25-3.80) and stage III rectal (OR 1.63, CI 1.13-2.40), as well as systemic therapy in stage IV CRC (OR 2.46, CI 1.75-3.52). Survival did not differ between <40 and 60-70 age groups. Survival was significantly higher for the 40-49 age group, but only in stage IV (HR 0.79, CI 0.67-0.94).<br /> Conclusions: EoCRC patients tended to receive more therapy than average age CRC patients with minimal survival gains. Additional research to identify optimal treatment strategies for eoCRC patients is required.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Incidence, treatment and relative survival of early-onset colorectal cancer in the Netherlands since 1989
    Swartjes, Hidde
    Brouwer, Nelleke P. M.
    De Nes, Lindsey C. F.
    Van Erning, Felice N.
    Verhoeven, Rob H. A.
    Vissers, Pauline A. J.
    De Wilt, Johannes H. W.
    EUROPEAN JOURNAL OF CANCER, 2022, 166 : 134 - 144
  • [32] Treatment patterns in metastatic early-onset rectal cancer
    Thompson, Nasya
    Waddell, Oliver
    Mccombie, Andrew
    Frizelle, Francis
    Glyn, Ms Tamara
    ANZ JOURNAL OF SURGERY, 2024,
  • [33] Early-onset pancreatic cancer: Clinical characteristics and survival outcomes
    Takeda, Tsuyoshi
    Sasaki, Takashi
    Inoue, Yosuke
    Okamoto, Takeshi
    Mori, Chinatsu
    Mie, Takafumi
    Furukawa, Takaaki
    Yamada, Yuto
    Kasuga, Akiyoshi
    Matsuyama, Masato
    Ozaka, Masato
    Takahashi, Yu
    Saiura, Akio
    Sasahira, Naoki
    PANCREATOLOGY, 2022, 22 (04) : 507 - 515
  • [34] Chemotherapy for ovarian cancer in the Netherlands: a population-based study on treatment patterns and outcomes
    E. Houben
    H. G. M. van Haalen
    W. Sparreboom
    J. A. Overbeek
    N. P. M. Ezendam
    J. M. A. Pijnenborg
    J. L. Severens
    M. P. P. van Herk-Sukel
    Medical Oncology, 2017, 34
  • [35] Neurotoxicity Outcomes in a Population-based Cohort of Elderly Patients Treated With Adjuvant Oxaliplatin for Colorectal Cancer
    Raphael, Michael J.
    Fischer, Hadas D.
    Fung, Kinwah
    Austin, Peter C.
    Anderson, Geoffrey M.
    Booth, Christopher M.
    Singh, Simron
    CLINICAL COLORECTAL CANCER, 2017, 16 (04) : 397 - +
  • [36] Early Discontinuation but Not the Timing of Adjuvant Therapy Affects Survival of Patients With High-Risk Colorectal Cancer: A Population-Based Study
    Ahmed, Shahid
    Ahmad, Imran
    Zhu, Tong
    Arnold, Florence P.
    Anan, Ghadeer Faiz
    Sami, Amer
    Yadav, Sunil K.
    Alvi, Riaz
    Haider, Kamal
    DISEASES OF THE COLON & RECTUM, 2010, 53 (10) : 1432 - 1438
  • [37] Adherence to Clinical Practice Guidelines and Colorectal Cancer Survival: A Retrospective High-Resolution Population-Based Study in Spain
    Carrasco-Pena, Francisco
    Bayo-Lozano, Eloisa
    Rodriguez-Barranco, Miguel
    Petrova, Dafina
    Marcos-Gragera, Rafael
    Carmona-Garcia, Maria Carmen
    Borras, Josep Maria
    Sanchez, Maria-Jose
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2020, 17 (18) : 1 - 17
  • [38] Chemotherapy for ovarian cancer in the Netherlands: a population-based study on treatment patterns and outcomes
    Houben, E.
    van Haalen, H. G. M.
    Sparreboom, W.
    Overbeek, J. A.
    Ezendam, N. P. M.
    Pijnenborg, J. M. A.
    Severens, J. L.
    van Herk-Sukel, M. P. P.
    MEDICAL ONCOLOGY, 2017, 34 (04)
  • [39] Early-Onset Basal Cell Carcinoma and Indoor Tanning: A Population-Based Study
    Karagas, Margaret R.
    Zens, M. Scot
    Li, Zhigang
    Stukel, Therese A.
    Perry, Ann E.
    Gilbert-Diamond, Diane
    Sayarath, Vicki
    Stephenson, Rita S.
    Barton, Dorothea
    Nelson, Heather H.
    Spencer, Steven K.
    PEDIATRICS, 2014, 134 (01) : E4 - E12
  • [40] The effect of comorbidities on outcomes in colorectal cancer survivors: a population-based cohort study
    Cuthbert, Colleen A.
    Hemmelgarn, Brenda R.
    Xu, Yuan
    Cheung, Winson Y.
    JOURNAL OF CANCER SURVIVORSHIP, 2018, 12 (06) : 733 - 743